PTC Therapeutics Inc
F:P91
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
PTC Therapeutics Inc
F:P91
|
US |
|
H
|
Heidelberg Materials AG
DUS:HEI
|
DE |
|
Carrefour SA
PAR:CA
|
FR |
|
E
|
Encompass Health Corp
SWB:HSOA
|
US |
|
C
|
Citigroup Inc
F:TRVC
|
US |
|
OMV AG
SIX:OMV
|
AT |
|
K
|
Kingfisher PLC
DUS:KFI1
|
UK |
Wall St Price Targets
P91 Price Targets Summary
PTC Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for P91 is 60.62 EUR with a low forecast of 41.84 EUR and a high forecast of 88.43 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is P91's stock price target?
Price Target
60.62
EUR
According to Wall Street analysts, the average 1-year price target for P91 is 60.62 EUR with a low forecast of 41.84 EUR and a high forecast of 88.43 EUR.
What is the Revenue forecast for PTC Therapeutics Inc?
Projected CAGR
2%
Over the last 13 years, the compound annual growth rate for Revenue has been 35%. The projected CAGR for the next 8 years is 2%.
What is the Operating Income forecast for PTC Therapeutics Inc?
Projected CAGR
-4%
The compound annual growth rate for Operating Income over the next 8 years is -4%.
What is the Net Income forecast for PTC Therapeutics Inc?
Projected CAGR
-3%
Over the last 13 years, the compound annual growth rate for Net Income has been 70%. The projected CAGR for the next 8 years is -3%.
